Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Moderna (MRNA)

Tipranks - Tipranks - Sun Apr 26, 2:50PM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Praxis Precision Medicines (PRAX) and Moderna (MRNA).

Claim 55% Off TipRanks

Praxis Precision Medicines (PRAX)

In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Praxis Precision Medicines, with a price target of $567.00. The company’s shares closed last Friday at $344.82.

According to TipRanks.com, Brisebois is a 3-star analyst with an average return of 2.2% and a 40.4% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Aquestive Therapeutics, and Tarsus Pharmaceuticals. ;'>

Currently, the analyst consensus on Praxis Precision Medicines is a Strong Buy with an average price target of $625.31, an 89.2% upside from current levels. In a report issued on April 15, TipRanks – Google also upgraded the stock to Buy with a $381.00 price target.

See today’s best-performing stocks on TipRanks >>

Moderna (MRNA)

William Blair analyst Myles Minter reiterated a Hold rating on Moderna today. The company’s shares closed last Friday at $50.73, close to its 52-week low of $29.25.

According to TipRanks.com, Minter is a 5-star analyst with an average return of 35.4% and a 58.7% success rate. Minter covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, CAMP4 Therapeutics Corporation, and Neumora Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Moderna with a $38.43 average price target, implying a -28.0% downside from current levels. In a report issued on April 21, Bernstein also maintained a Hold rating on the stock with a $45.00 price target.

Read More on PRAX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).